<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;COPD management in the long-term care setting.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American Medical Directors Association (AMDA). COPD management in the long-term care setting. Columbia (MD): American Medical Directors Association (AMDA); 2010. 42 p.  [50 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: American Medical Directors Association (AMDA). COPD management in the long-term care setting. Columbia (MD): American Medical Directors Association (AMDA); 2003. 32 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Chronic airway obstruction, not elsewhere classified  (496); Electrocardiogram  (89.52); General physical examination  (89.7)"/><FieldValue Value="MSH: Adrenal Cortex Hormones ; Adrenergic beta-Agonists ; Albuterol ; Androstadienes ; Anti-Bacterial Agents ; Blood Cell Count ; Blood Chemical Analysis ; Bronchodilator Agents ; Budesonide ; Clinical Chemistry Tests ; Diagnosis, Differential ; Diagnostic Tests, Routine ; Diuretics ; Drug Therapy, Combination ; Electrocardiography ; Ethanolamines ; Exercise ; Influenza Vaccines ; Long-Term Care ; Medical History Taking ; Medical Records ; Medication Therapy Management ; Nebulizers and Vaporizers ; Nutritional Sciences ; Organizational Culture ; Oximetry ; Oxygen Inhalation Therapy ; Palliative Care ; Patient Care Planning ; Patient Care Team ; Patient Education as Topic ; Physical Examination ; Pneumococcal Vaccines ; Prednisone ; Pulmonary Disease, Chronic Obstructive ; Respiratory Tract Infections ; Scopolamine Derivatives ; Severity of Illness Index ; Smoking Cessation ; Spirometry ; Suction ; Theophylline "/><FieldValue Value="MTH: Adrenal Cortex Hormones ; Adrenergic beta-Agonists ; Anti-Bacterial Agents ; Antibiotics ; blood cell count ; Blood Chemical Analysis ; Cessation of smoking ; Chronic airway obstruction, NEC in ICD9CM_2014 ; Chronic Obstructive Airway Disease ; Clinical Chemistry Tests ; Combination Drug Therapy ; Differential Diagnosis ; Electrocardiogram ; Electrocardiography ; Ethanolamines ; Exercise ; Influenza virus vaccine ; long-term care ; Medical Records ; Oximeter ; Oxygen saturation measurement ; Oxygen Therapy Care ; Palliative Care ; Patient education (procedure) ; physical examination ; Plain chest X-ray ; Pneumococcal vaccine ; Prednisone ; Science of nutrition ; Spacer inhalation therapy ; Spirometer (device) ; Suction drainage ; Theophylline "/><FieldValue Value="PDQ: budesonide ; prednisone ; theophylline "/><FieldValue Value="SNOMEDCT_US: Albuterol  (372897005); Albuterol  (91143003); Antibacterial agent  (346325008); Antibacterial agent  (419241000); Antibiotic  (255631004); Beta-adrenoceptor agonist  (349920008); Beta-adrenoceptor agonist  (373227004); Blood cell count  (88308000); Blood chemistry  (166312007); Bronchodilator  (353866001); Bronchodilator  (372580007); Budesonide  (108622005); Budesonide  (395726003); Chronic obstructive pulmonary disease finding  (13645005); Chronic obstructive pulmonary disease finding  (413846005); Corticoid preparation  (21568003); Corticoid preparation  (79440004); Differential diagnosis  (47965005); Diuretic  (30492008); Diuretic  (372695000); Electrocardiographic procedure  (29303009); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); Family education  (311403008); Family education  (460616007); Influenza virus vaccine  (396425006); Influenza virus vaccine  (46233009); Medical record  (129465004); Oxygen saturation measurement  (104847001); Oxygen saturation measurement  (264598005); Oxygen therapy  (57485005); Palliative care  (103735009); Patient education  (311401005); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Plain chest X-ray  (399208008); Pneumococcal vaccine  (333598008); Pneumococcal vaccine  (398730001); Prednisone  (10312003); Prednisone  (116602009); Pulse oximetry  (252465000); Pulse oximetry  (708065004); Respiratory tract infection  (275498002); Spirometer  (303501006); Spirometry  (127783003); Suction drainage  (274441001); Theophylline  (372810006); Theophylline  (66493003); Tiotropium bromide  (425812008)"/><FieldValue Value="SPN: OXIMETER "/><FieldValue Value="UMD: Oximeters  (12-853); Physiologic Monitor Modules, Electrocardiography  (20-771); Radiographic Systems, Digital, Chest  (18-431); Spirometers  (13-674)"/></Field></Section><Section SecID="394" OrdBy="200" Name="Regulatory Alert"><Field FieldID="154" OrdBy="205" ID="395" Name="FDA Warning/Regulatory Alert" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse:&lt;/strong&gt; This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;&lt;a href=&quot;http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm437415.htm&quot; title=&quot;FDA Web site&quot; target=&quot;_blank&quot;&gt;March 9, 2015 &amp;ndash; Chantix and Varenicline&lt;/a&gt;: The U.S. Food and Drug Administration (FDA) is warning that the prescription smoking cessation medicine Chantix (varenicline) can change the way people react to alcohol. Interactions between alcohol and Chantix have resulted in some patients experiencing increased intoxicating effects of alcohol, sometimes associated with aggressive behavior and/or amnesia. In addition, rare accounts of seizures in patients treated with Chantix have been reported. FDA has approved changes to the Chantix label to warn about these risks. Refer to the Drug Safety Communication for a detailed data summary. &lt;/li&gt;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Chronic obstructive pulmonary disease (COPD)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Family Practice" /><FieldValue Value="Geriatrics" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Pulmonary Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Allied Health Personnel" /><FieldValue Value="Dietitians" /><FieldValue Value="Health Care Providers" /><FieldValue Value="Nurses" /><FieldValue Value="Occupational Therapists" /><FieldValue Value="Patients" /><FieldValue Value="Pharmacists" /><FieldValue Value="Physical Therapists" /><FieldValue Value="Physicians" /><FieldValue Value="Respiratory Care Practitioners" /><FieldValue Value="Social Workers" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To improve the quality of care for patients with chronic obstructive pulmonary disease (COPD) in long-term care settings &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To guide staff and practitioner practices and performance &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Residents of long-term care facilities at risk for or with confirmed chronic obstructive pulmonary disease (COPD)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Diagnosis/Evaluation/Risk Assessment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Screening newly admitted patient for chronic obstructive pulmonary disease (COPD) and risk factors for COPD &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Differential diagnosis&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Assessing symptoms and physical signs &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Medical history &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Physical examination &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Laboratory testing, including chest x-ray, complete blood count, chemistry panel, electrocardiogram, pulse oximetry, spirometry &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessing and classifying the severity of COPD (Stage I-IV) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessing the stability of the patient's COPD &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Obtaining input from all members of the interdisciplinary team &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessing the patient's functional status &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Written summary of the patient's condition &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management/Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Developing an individualized care plan and defining treatment goals &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Implementing facility-wide programs and policies to encourage smoking cessation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Nonpharmacologic interventions, including patient and family education, nutrition, and exercise &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Prescribing supplemental oxygen therapy if appropriate &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ensuring that the patient is protected against respiratory tract infections through pneumococcal and influenza vaccinations &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pharmacologic interventions for stable COPD (step-wise approach)&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Short-acting beta-2 agonist (e.g., albuterol metered-dose inhaler [MDI]) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Tiotropium bromide or long-acting beta-2 agonist &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Combination therapy with tiotropium bromide and long-acting beta-2 agonist &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Inhaled corticosteroid (combination product, e.g., fluticasone/salmeterol, budesonide/formoterol) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Long-acting theophylline &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Oxygen, diuretics, antibiotics, as indicated &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of acute exacerbations&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Patient education (inhalation technique, use of spacer devices) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Bronchodilators (short-acting beta 2 agonist and ipratropium MDI with spacer or hand-held nebulizer as needed) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Addition of long-acting bronchodilator if patient is not using one &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Corticosteroids (oral prednisone, inhaled corticosteroid) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Antibiotics &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Suctioning &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Hospitalization &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Managing comorbidities and complications associated with COPD &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evaluating patient's condition for end-stage and providing palliative end-stage care if appropriate &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Monitoring patient&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Symptoms and functional ability &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Use of medications, with adjustments as necessary &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Facility's management of COPD &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Overall morbidity and mortality associated with chronic obstructive pulmonary disease (COPD) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patient quality of life &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Severity and frequency of acute exacerbations of COPD &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Symptom control and patient perception of symptom control &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patient function in activities of daily living (ADLs) and participation in social activities. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adverse effects of medication &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Resource utilization and patient care costs &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Medline, PubMed, and geriatric-specific journals such as the Journal of the American Medical Directors Association (JAMDA), Annals of Long Term Care, and Journal of the American Geriatrics Society (JAGS) were searched from May 2009 through February 2011. Studies were included if they met the following criteria:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Studies that are valid, consistent, applicable and clinically relevant &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Studies where the recommendation is supported by fair evidence (based on studies that are valid, but there are some concerns about the volume, consistency, applicability and clinical relevance of the evidence that may cause some uncertainty but are not likely to be overturned by other evidence) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Searches were specific to the guideline topic under consideration.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review" /><FieldValue Value="Review of Published Meta-Analyses" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Original guidelines are developed by interdisciplinary workgroups, using a process that combines evidence and consensus-based approaches. Workgroups include practitioners and others involved in patient care in long-term care facilities. Beginning with a general guideline developed by an agency, association, or organization such as the Agency for Healthcare Research and Quality (AHRQ), pertinent articles and information, and a draft outline, each group works to make a concise, usable guideline that is tailored to the long-term care setting. Because scientific research in the long-term care population is limited, many recommendations are based on the expert opinion of practitioners in the field. A bibliography is provided for individuals who desire more detailed information.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Guideline revisions are completed under the direction of the Clinical Practice Guideline Steering Committee. The committee incorporates information published in peer-reviewed journals after the original guidelines appeared as well as comments and recommendations not only from experts in the field addressed by the guideline but also from &quot;hands-on&quot; long-term care practitioners and staff.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Published cost analyses were reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;All American Medical Directors Association (AMDA) clinical practice guidelines undergo external review. The draft guideline is sent to approximately 175+ reviewers. These reviewers include American Medical Directors Association physician members and independent physicians, specialists, and organizations that are knowledgeable of the guideline topic and the long-term care setting. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;AMDA's guidelines are supported by the following associations/organizations, who are members of its Clinical Practice Guideline Steering Committee. These associations/organizations all have representatives who participate in the external review phase and officially sign off on the guideline before publication: American Association of Homes and Services for the Aging (Now LeadingAge); American College of Health Care Administrators; American Geriatrics Society; American Health Care Association; American Society of Consultant Pharmacists; Gerontological Advanced Practice Nurses Association; Direct Care Alliance; National Association of Directors of Nursing Administration in Long-Term Care; National Association of Health Care Assistants.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;&lt;strong&gt;Note from the American Medical Directors Association (AMDA) and the National Guideline Clearinghouse (NGC)&lt;/strong&gt;&lt;/em&gt;: The original full-text guideline provides an algorithm on &quot;COPD Management&quot; to be used in conjunction with the written text. Refer to the &quot;Guideline Availability&quot; field for information on obtaining the algorithm, as well as the full text of the guideline, which provides additional details.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recognition&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In the long-term care (LTC) facility, patients with chronic obstructive pulmonary disease (COPD) are likely to fall into one of the following four categories:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Those with a primary diagnosis of COPD &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Those with a secondary diagnosis of COPD &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Those who have unrecognized COPD or who develop symptoms while residing in the facility &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Those with end-stage COPD (e.g., patients with chronic hypoxia, pulmonary hypertension, skeletal muscle wasting) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 1&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Screen the newly admitted patient for COPD and risk factors for COPD&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;On admission or during the pre-admission assessment, assess the patient's respiratory status. Ask the patient and family members if the patient has a history of lung disease or other signs and symptoms that may indicate lung problems or risk factors for COPD (see Table 1 in the original guideline document).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Assessment&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 2&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Develop a differential diagnosis&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Few symptoms and physical signs clearly differentiate COPD from other respiratory conditions such as asthma. Chronic airflow limitation may also be associated with diseases such as congestive heart failure (CHF), lung cancer, and pulmonary tuberculosis. Both asthma and CHF may produce symptoms of cough with sputum production, dyspnea on exertion, and wheezing, all of which are also symptoms of COPD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;It is suggested that the following information, if available, be documented in the medical history of a new patient with known or suspected COPD:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Appropriateness of current medical treatments for pulmonary conditions &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exposure to risk factors for COPD such as smoking and occupational or environmental exposures &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Family history of COPD or other chronic respiratory disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;History of allergy, asthma, nasal polyps, respiratory infections in childhood, sinusitis, and other respiratory diseases &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;History of exacerbations or hospitalizations for a respiratory disorder &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Impact of disease on the patient&amp;rsquo;s life, including activity limitations and effects on family and on psychosocial functioning (i.e., feelings of anxiety or depression) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pattern of symptom development &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Possibilities for reducing risk factors, especially smoking cessation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Presence of comorbidities (e.g., heart disease, malignancies, musculoskeletal disorders, obesity) that may contribute to activity restriction &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Presence of deforming enlargement of the fingertips (&quot;clubbing&quot;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Social and family support available to the patient &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;The following diagnostic tests (if not previously done) are recommended to develop a differential diagnosis:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Brain natriuretic peptide (to help to differentiate COPD from CHF) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Chest x-ray &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Complete blood count &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Chemistry panel &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Electrocardiogram &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pulse oximetry at rest and with activity &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Spirometry &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Key Indicators for Considering a Diagnosis of COPD&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Table: Key Indicators for Considering a Diagnosis of COPD&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consider COPD if any of these indicators are present in a patient aged &amp;gt;40. Although these indicators are not in themselves diagnostic, the presence of multiple indicators increases the probability of a diagnosis of COPD.&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;&lt;strong&gt;Dyspnea that is&lt;/strong&gt;:&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Progressive &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Usually worse with exercise &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Persistent &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Described by the patient as an &quot;increased effort to breathe,&quot; &quot;heaviness,&quot; &quot;air hunger,&quot; or &quot;gasping&quot; &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;&lt;strong&gt;Chronic cough&lt;/strong&gt;&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;May be intermittent &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;May be unproductive &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;&lt;strong&gt;Chronic sputum production&lt;/strong&gt;&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Any pattern of chronic sputum production may indicate COPD &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;&lt;strong&gt;History of exposure to risk factors&lt;/strong&gt;&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Tobacco smoke &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Occupational dusts and chemicals &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Smoke from home cooking and heating fuel &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;span class=&quot;Note&quot;&gt;Source: Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (updated 2008). Available at: &lt;a href=&quot;http://www.goldcopd.org/&quot; title=&quot;GOLD Web site&quot;&gt;http://www.goldcopd.org/&lt;/a&gt;.&lt;/span&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 3&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Assess the severity of the patient's COPD&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Assessment of the severity of COPD guides treatment planning and is important for measuring improvement. Typically, the disease is classified as mild, moderate, severe, or very severe (see Table 4 in the original guideline document). Disease severity as determined by pulmonary function testing, however, does not necessarily correlate with functional capacity and subjective sensations of breathlessness.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The 6-minute walk test is a reproducible measure of the level of everyday impairment and exercise tolerance.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 4&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Assess the stability of the patient's COPD&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients with COPD should be assessed on admission and frequently during the course of care for worsening symptoms that may reflect &lt;strong&gt;acute exacerbation&lt;/strong&gt; of their disease (an acute change in baseline dyspnea, cough, or sputum beyond day-to-day variability that is sufficient to warrant a change in therapy).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Acute exacerbations of COPD require urgent treatment to prevent respiratory failure. (See Step 14.)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 5&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Obtain input from all members of the interdisciplinary team&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Within a reasonable period of time following admission or recognition of COPD, the interdisciplinary team should evaluate the patient's care, physical limitations, and overall quality of life.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 6&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Assess the patient's functional status&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This should be done at baseline, quarterly, and following an acute exacerbation, or when comorbid disease is present. Practitioners should assess function during routine visits.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 7&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Summarize the patient's condition&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The practitioner's written summary of the patient's medical condition should:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Describe the patient's medical conditions and stability, including control of COPD and severity of associated complications. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assess the impact of COPD on the patient's functioning and quality of life. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Where relevant, provide reasons why other suspected diagnoses were not pursued (e.g., patient is too frail, has a terminal condition, is unwilling to undergo further interventions; further evaluation is not consistent with the plan of care based on the patient's or family's wishes). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;List applicable treatments for the patient's COPD and coexisting medical conditions. Give reasons for recommending the use or nonuse of identified treatment options in this patient, considering his or her overall state of health, advance directives, and preferences. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Treatment&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Because COPD is by definition a chronic disorder that is only partially reversible, complete resolution of symptoms and reversal of damage are not realistic goals of treatment. It is usually possible, however, to significantly improve exertional shortness of breath and physical endurance, thus improving patients' quality of life. Management of COPD has three components:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Prevention of additional lung damage &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Prevention and management of acute exacerbations &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Optimization of current lung function &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Surgical interventions to treat COPD are usually not considered in the LTC setting because of the limited life expectancy and comorbidities of most patients in this setting. For this reason, these options are not addressed in this guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 8&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Develop an individualized care plan and define treatment goals&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The treatment of COPD should be individualized, taking into account the patient's comorbidities, prognosis, life expectancy, and preferences, including those expressed in advance care directives. In general, however, the following treatment goals are appropriate for most patients with COPD:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Address complications (e.g., heart failure, polycythemia, severe hypoxemia). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Avoid aggravating factors (e.g., bronchial irritants, harmful medications, secondhand smoke). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Avoid the use of costly, non&amp;ndash;evidence-based treatment options. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Educate the patient and family or other caregivers. (See Step 10.) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ensure that the patient's influenza and pneumococcal immunizations are up-to-date. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Maximize exercise tolerance. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reduce acute exacerbations. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reduce cough, secretions, and shortness of breath. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Relieve any reversible airway obstruction. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Relieve depression and anxiety. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stop cigarette smoking. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treat and, to the extent possible, prevent infection. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 9&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Implement facility-wide programs and policies to encourage smoking cessation&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Pharmacotherapy is recommended when counseling is insufficient to help patients stop smoking. Consider prescribing nicotine replacement therapy in addition to referring patients to counseling for smoking cessation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Care managers and caregivers should be aware that exposure to secondhand smoke may exacerbate COPD and cause relapse in individuals who are trying to quit smoking. Facilities should ensure that any designated smoking areas are sufficiently separated from non-smoking patients, staff, and visitors.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 10&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Implement nonpharmacologic interventions&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patient education, nutrition, and exercise are important components of the nonpharmacologic management of stable COPD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 11&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Prescribe supplemental oxygen therapy if appropriate&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Initiate oxygen therapy for patients with very severe (Stage IV) COPD if:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Arterial oxygen pressure (PaO&lt;sub&gt;2&lt;/sub&gt;) is at or below 55 mm Hg or arterial oxygen percent saturation (SaO&lt;sub&gt;2&lt;/sub&gt;) is at or below 88%, with or without hypercapnia; &lt;em&gt;or&lt;/em&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;PaO&lt;sub&gt;2&lt;/sub&gt; is between 55 mm Hg and 60 mm Hg or SaO&lt;sub&gt;2&lt;/sub&gt; is 88%, if there is evidence of pulmonary hypertension, peripheral edema suggesting congestive heart failure (CHF), or polycythemia (hematocrit over 55%). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;When initiating long-term oxygen therapy, consider checking pulse oximetry periodically during sleep. Continue this practice only if satisfied that it adds to the safety and efficacy of oxygen therapy at night.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 12&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Ensure that the patient is protected against respiratory tract infections&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Influenza vaccine is advised yearly for all individuals with COPD. Pneumococcal vaccine is also advised for all COPD patients, regardless of age.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 13&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Implement appropriate pharmacologic interventions&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Refer to Figure 1 in the original guideline document for an algorithm for pharmacological treatment of chronic obstructive pulmonary disease (COPD). In addition, Table 8 in the original guideline summarizes the effects of frequently used medications in patients with COPD.&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Guiding Principles for COPD Pharmacotherapy in the Long-Term Care Setting&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Table: Guiding Principles for COPD Pharmacotherapy in the Long-Term Care Setting&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Medications should be used in combination with nonpharmacologic approaches and initiated only after determining that nonpharmacologic therapies have provided insufficient symptom relief. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Medications with the fewest likely side effects should be selected and used at the lowest effective doses. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Regular treatment with long-acting bronchodilators is more effective and convenient than regular treatment with short-acting bronchodilators. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Combining bronchodilators of different pharmacologic classes may improve efficacy and decrease the risk of side effects compared with increasing the dose of a single bronchodilator. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;The medication delivery system should be tailored to the patient's needs. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Regular treatment needs to be maintained at the same level for long periods of time unless significant side effects occur or the disease worsens. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Treatment tends to be cumulative, with more medications required as the disease state worsens. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Patients and caregivers should be trained in the proper administration of inhaled medications. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;The patient's response to therapy and side effects should be carefully assessed and treatment adjusted accordingly. &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;span class=&quot;Note&quot;&gt;Adapted from: Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (updated 2008). Available at: &lt;a href=&quot;http://www.goldcopd.org&quot; title=&quot;GOLD Web site&quot;&gt;http://www.goldcopd.org&lt;/a&gt;.&lt;/span&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;: Stepwise Approach to Pharmacotherapy for Stable COPD&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Table: Stepwise Approach to Pharmacotherapy for Stable COPD&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Short-acting beta-2 agonist (e.g., albuterol metered-dose inhaler [MDI]) for mild symptoms PRN* &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Tiotropium bromide or long-acting beta-2 agonist &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Combination therapy with tiotropium bromide and long-acting beta-2 agonist &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Add inhaled corticosteroid (use combination product, e.g., fluticasone/salmeterol, budesonide/formoterol) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Consider long-acting theophylline if symptoms are still present and repeated exacerbations occur &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Oxygen, diuretics, antibiotics, as indicated &lt;/li&gt;&#xD;&#xA;            &lt;/ol&gt;&#xD;&#xA;            &lt;p class=&quot;Note&quot;&gt;*Should be available and used on a PRN (as needed) basis throughout the entire course of the disease.&lt;/p&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;span class=&quot;Note&quot;&gt;Adapted from: Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (updated 2008). Available at: &lt;a href=&quot;http://www.goldcopd.org&quot; title=&quot;GOLD Web site&quot;&gt;http://www.goldcopd.org&lt;/a&gt;&lt;/span&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Proper Use of Inhaled Medications&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;When an inhaled medication appears to be ineffective, ensure that it is being properly administered before deciding to prescribe a different medication.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;It is critical that staff administering inhaled medications demonstrate competency to do so. Patients' ability to use their inhalers independently should also be evaluated. Patients who have demonstrated that they can use and store their inhalers safely and correctly should be permitted to have access to a rescue inhaler if they wish. Patients who have rescue inhalers must be able to tell nursing staff when they used the inhaler and how many doses they took, so that the nursing staff can note this in the medication administration record. Patients who self-administer rescue inhaler therapy should be re-assessed periodically and their refills monitored for overuse.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Palliative Care for COPD&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Palliative care is not solely for patients in the final days or months of life.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The foundation of dyspnea palliation for patients with COPD is to optimize medical care of COPD. Also consider nonpharmacologic interventions such as emotional support, relaxation techniques, and consultation with occupational and physical therapists for suggestions regarding breathing techniques, energy conservation, and positioning.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 14&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Treat acute exacerbations of COPD promptly&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Acute exacerbations of COPD often follow upper respiratory tract infections and begin with dyspnea, followed by increased purulence and volume of sputum. Table 11 in the guideline document lists signs and symptoms of an acute exacerbation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 14.1&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recognize and report the acute exacerbation&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Train nursing assistants to recognize and immediately report to a nursing supervisor any acute change of condition in a patient with COPD (including any change in baseline dyspnea, cough, sputum, or mental status beyond normal day-to-day variation).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 14.2&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Implement initial treatment of the acute exacerbation, assess the severity of the episode, and contact the practitioner&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients with COPD should have as-needed (PRN) orders for rescue medications (e.g., ipratropium, short-acting beta-2 agonists), which should be given as soon as an exacerbation is identified. The nurse should complete an assessment of the patient and contact the practitioner for further orders. The use of a protocol for physician notification may be helpful when reporting a patient's symptoms to the practitioner by telephone. Table 12 in the original guideline document provides an example of a &quot;call sheet&quot; that nurses may wish to use.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 14.3&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Treat the acute exacerbation&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The practitioner should increase the dose and frequency of bronchodilator therapy in addition to any prescribed rescue regimen already ordered.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Consider additional diagnostic testing (e.g., chest x-ray, chemistry panel, complete blood count, electrocardiogram) to evaluate for precipitating events or associated conditions such as CHF or pneumonia. Pulmonary embolism may also be considered in the differential diagnosis.&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Treatment of an Acute Exacerbation of COPD&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Table: Treatment of an Acute Exacerbation of COPD&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Patient Education&lt;/strong&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Check inhalation technique &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Consider use of spacer devices &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;strong&gt;Bronchodilators&lt;/strong&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Short-acting beta-2 agonist and ipratropium MDI with spacer or hand-held nebulizer as needed &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Consider adding long-acting bronchodilator if patient is not using one &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;strong&gt;Corticosteroids (actual dose may vary)&lt;/strong&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Prednisone 30&amp;ndash;40 mg/d orally for 10&amp;ndash;14 days &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Consider using an inhaled corticosteroid &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;strong&gt;Antibiotics&lt;/strong&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;May be initiated in patients with altered sputum characteristics &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Choice should be based on local bacterial resistance patterns&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Amoxicillin/ampicillin, cephalosporins &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Doxycycline &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Macrolides &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;If the patient has failed prior antibiotic therapy, consider&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Amoxicillin/clavulanate &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Respiratory fluoroquinolones &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;span class=&quot;Note&quot;&gt;Source: American Thoracic Society/European Respiratory Society. Standards for the diagnosis and management of patients with COPD. 2004. Available at: &lt;a href=&quot;http://www.thoracic.org/clinical/copd-guidelines/&quot; title=&quot;ATS Web site&quot;&gt;http://www.thoracic.org/clinical/copd-guidelines/&lt;/a&gt;.&lt;/span&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;See also Table 14 in the original guideline document for guidelines on the appropriate use of suctioning in COPD patients.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 14.4&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Decide whether the patient with an acute exacerbation of COPD should be hospitalized&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Table 15 in the original guideline document lists factors that may help to determine whether hospitalization is appropriate for an acute exacerbation of COPD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 14.5&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;When the acute exacerbation resolves, taper or discontinue medications prescribed to treat it&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Oral corticosteroids may be indicated during an acute exacerbation of COPD, but in most instances these agents should be discontinued after 10 to 14 days of therapy. Adjust bronchodilator regimens as appropriate.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 15&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Manage comorbidities associated with COPD&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 16&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Consider specialty referral&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Referral to a cardiologist or pulmonologist may be appropriate in any of the following clinical situations:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Acute event requiring hospitalization &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Airflow limitation despite only a short smoking history &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Frequent exacerbations of COPD &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Heart failure that is difficult to manage &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Practitioner uncertainty about the patient's diagnosis or management &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Progressive symptoms despite optimal medication &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Rapidly progressive pulmonary impairment despite usual care &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Severe dyspnea &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Specialty referral is inappropriate, however, for many patients with COPD in the LTC setting. When determining whether to make a specialty referral, consider the patient's cognitive and functional status, expressed preferences, life expectancy, and severity of disease, as well as the availability of and access to subspecialty input, the capabilities and experience of the interdisciplinary care team, and the immediacy of the clinical need.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 17&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Determine when the patient's condition is end-stage&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Before the patient with COPD develops advanced disease, he or she should be counseled about end-of-life planning and encouraged to draw up advance directives, if this has not already been done.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;End-of-life care for the patient with end-stage COPD may include fluids, oxygen, and sedation, if appropriate. Administer fluids judiciously; at the end of life they may increase pulmonary congestion. Benzodiazepines and opioids may be given to relieve dyspnea. In end-of-life care, balance the potential adverse effects of these agents (respiratory depression and decreased mental alertness) against the symptomatic relief they offer the patient. Consider and respect the patient's expressed wishes concerning the preference for symptom relief or alertness.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Monitoring&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Because COPD is a progressive disorder, patients must be reassessed regularly. At a minimum, reassessment of the patient's overall functioning should occur at each quarterly review and at any time a significant change is noted in the patient's condition. The progressive nature of COPD also means that preventing further decline in a patient's level of functioning may not always be a realistic therapeutic goal. Periodic reappraisal of the goals of therapy is an essential component of ongoing care. The practitioner should address the status of the patient's COPD in his or her periodic notes, which should document the reasons for treatment choices and oversight of the overall plan of care developed by the interdisciplinary team.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 18&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Monitor the patient's symptoms and functional ability&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Table 17 in the original guideline document lists aspects of the patient's status that should be monitored at regular intervals.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 19&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Monitor the use of medications to treat COPD&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Monitor medications regularly to ensure that drug interactions and side effects are addressed promptly. Review medications at any time that a significant change is noted in the patient's clinical condition. Consider eliminating or reducing dosages of medications that are associated with adverse effects or that produce no demonstrable benefit. To the extent possible, use pharmacologic agents with the lowest side-effect profile. Document adverse medication effects and the steps taken to correct them in the patient's record.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 20&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Monitor the facility's management of COPD&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Systematic monitoring is needed to determine the extent to which a long-term facility is successful in managing COPD. A facility may wish to select several of the indicators in Table 18 of the original guideline document that are most relevant to its population and staff for inclusion in its quality improvement process. The medical director should be actively involved in this process.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Algorithms are provided in the original guideline document for:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Chronic obstructive pulmonary disease (COPD) management &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pharmacologic treatment of COPD &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of evidence supporting the recommendations is not specifically stated.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The guideline was developed by an interdisciplinary work group using a process that combined evidence- and consensus-based approaches. Because scientific research in the long-term care population is limited, many recommendations are based on the expert opinion of practitioners in the field.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Guideline implementation can help ameliorate symptoms of the disease and significantly improve patients' quality of life. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Outcomes that may be expected from the implementation of this guideline include the following:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Earlier identification and better differential diagnosis of COPD. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Improvements in:&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Appropriate use of oxygen therapy and medications to treat COPD, resulting in improved resource utilization and decreased patient-care costs &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Awareness and understanding of the disease among both affected patients and their caregivers &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Comfort care for patients with end-stage COPD &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Patient function in activities of daily living (ADLs) and participation in social activities &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Patient quality of life &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Staff satisfaction and confidence in their ability to manage COPD &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Symptom control and patient perception of symptom control &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Understanding of when and how to initiate palliative care &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Reductions in:&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Anxiety and depression caused by shortness of breath and other COPD symptoms &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Frequency of acute exacerbations of COPD &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Frequency of hospital transfers for acute exacerbations of COPD &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Incidence of sleep disturbance &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Prevalence of smoking in the facility &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Rates of viral and bacterial infections in COPD patients &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients receiving &lt;em&gt;bupropion&lt;/em&gt; or &lt;em&gt;varenicline&lt;/em&gt; for smoking cessation should be closely monitored for development of any of the following neuropsychiatric symptoms: agitation, behavior change, depressed mood, hostility, suicidal thoughts and behavior, or attempted suicide. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Inhaled beta-2 adrenergic agonists&lt;/em&gt;: these agents (especially at higher doses) may cause systemic side effects such as anxiety, arrhythmia, insomnia, tachycardia, and tremor. The long-acting beta-2 agonists salmeterol, formoterol, and arformoterol must be taken only as prescribed (i.e., for maintenance therapy), and never used as rescue medications. Agents in this class have been associated with a small but significant increase in asthma-related deaths. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Theophylline&lt;/em&gt;: Although higher doses of theophylline are effective bronchodilators in COPD patients, inhaled bronchodilators are preferred in elderly patients because of theophylline's potential for toxicity and drug interactions. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Inhaled corticosteroids&lt;/em&gt;: Because oral inhalation of steroid products may lead to oral thrush, patients should be encouraged to swish their mouths with a small amount of water and expectorate after each dose. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Suctioning&lt;/em&gt;: Suctioning may increase the patient's comfort, but in some cases it may cause discomfort and increase shortness of breath. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Benzodiazepines and opioids&lt;/em&gt;: In end-of-life care, balance the potential adverse effects of these agents (respiratory depression and decreased mental alertness) against the symptomatic relief they offer the patient. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;This clinical practice guideline is provided for discussion and educational purposes only and should not be used or in any way relied upon without consultation with and supervision of a qualified physician based on the case history and medical condition of a particular patient. The American Medical Directors Association (AMDA), its heirs, executors, administrators, successors, and assigns hereby disclaim any and all liability for damages of whatever kind resulting from the use, negligent or otherwise, of this clinical practice guideline. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The utilization of AMDA's Clinical Practice Guideline does not preclude compliance with State and Federal regulation as well as facility policies and procedures. They are not substitutes for the experience and judgment of clinicians and caregivers. The Clinical Practice Guidelines are not to be considered as standards of care but are developed to enhance the clinicians' ability to practice. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The corporate supporters of this guideline provided funding without condition of product use, formulary status or purchasing commitment. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Long-term care facilities care for a variety of individuals, including younger patients with chronic diseases and disabilities, short-stay patients needing postacute care, and very old and frail individuals suffering from multiple comorbidities. When a workup or treatment is suggested, it is crucial to consider if such a step is appropriate for a specific individual. A workup may not be indicated if the patient has a terminal or end-stage condition, if it would not change the management course, if the burden of the workup is greater than the potential benefit, or if the patient or his or her proxy would refuse treatment. It is important to carefully document in the patient's medical record the reasons for decisions not to treat or perform a workup or for choosing one treatment approach over another. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The implementation of this clinical practice guideline (CPG) is outlined in four phases. Each phase presents a series of steps, which should be carried out in the process of implementing the practices presented in this guideline. Each phase is summarized below.&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Recognition&lt;/strong&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Define the area of improvement and determine if there is a CPG available for the defined area. Then evaluate the pertinence and feasibility of implementing the CPG. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Assessment&lt;/strong&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Define the functions necessary for implementation and then educate and train staff. Assess and document performance and outcome indicators and then develop a system to measure outcomes. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Implementation&lt;/strong&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Identify and document how each step of the CPG will be carried out and develop an implementation timetable. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Identify individual responsible for each step of the CPG. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Identify support systems that impact the direct care. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Educate and train appropriate individuals in specific CPG implementation and then implement the CPG. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Monitoring&lt;/strong&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Evaluate performance based on relevant indicators and identify areas for improvement. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Evaluate the predefined performance measures and obtain and provide feedback. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Audit Criteria/Indicators" /><FieldValue Value="Clinical Algorithm" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="End of Life Care" /><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American Medical Directors Association (AMDA). COPD management in the long-term care setting. Columbia (MD): American Medical Directors Association (AMDA); 2010. 42 p.  [50 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2003 (revised 2010)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="American Medical Directors Association - Professional Association" /></Field><Field FieldID="123" OrdBy="1230" ID="448" Name="Guideline Developer Comment" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Organizational participants included:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;American Association of Homes and Services for the Aging &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;American College of Health Care Administrators &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;American Geriatrics Society &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;American Health Care Association &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;American Society of Consultant Pharmacists &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Gerontological Advanced Practice Nurses Association &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;National Association of Directors of Nursing Administration in Long-Term Care &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;National Association of Health Care Assistants &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;American Medical Directors Association&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Boehringer Ingelheim Corporation and Dey Pharma, L.P. are corporate supporters of this guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Clinical Practice Guideline Steering Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Clinical Practice Committee (CPC) Chair&lt;/em&gt;: Charles Cefalu, MD, MS&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;CPG Chair&lt;/em&gt;: Mario Cornacchione, DO, CMD&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Steering Committee Members&lt;/em&gt;: Charles Cefalu, MD, MS (&lt;em&gt;Chair&lt;/em&gt;); Sherrie Dornberger, RNC, CDONA, FDONA; Sandra Fitzler, RN; Marianna Grachek, MSN CNHA CALA; Joseph Gruber, RPh, FASCP, CGP; Susan M. Levy, MD, CMD; Evvie F. Munley; Jonathan Musher, MD, CMD; Barbara Resnick, PhD, CRNP; William Simonson, PharmD, FASCP, CGP&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Original Panel Members&lt;/em&gt;: *Susan Levy, MD, CMD (&lt;em&gt;Chair&lt;/em&gt;); Beth McCarty, CNA; *Harlan Martin, RPH, CCP, FASCP (&lt;em&gt;Facilitator&lt;/em&gt;); Erin Rawling, OT; Pam Brummitt, MA, RDLD; Virginia &quot;Ginger&quot; Saunders, RN; *Charles A. Cefalu, MD, MS; Tom Snader, PharmD, FASCP; Nancy DeFranco, RNC; Susan Sragow, LSW; Vincent DeLuzio, Rec. Therapist; Brendan Thomson, MD, MBA; Lynn Godar-Mollica, APRN; Jerome Wilborn, MD; Penny Hanisch, CRCP&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Contributors to update&lt;/em&gt;: *Mario Cornacchione, DO, CMD (&lt;em&gt;Chair&lt;/em&gt;); *Charles Cefalu, MD, MS (&lt;em&gt;CPG Project Chair&lt;/em&gt;); Eli Pick, CNHA, CAS, FACHCA; Terry Oshea, PharmD, CGP; Steve Aldridge, R.Ph., M.Ad., CGP, FASCP, CHCA; Albert Riddle, MD, CMD; Diane Sanders-Cepeda, DO; William Smucker, MD, CMD; Charles A. Crecelius, MD, PhD, CMD; Barney Spivack, MD, CMD; Malcolm Fraser, MD, CMD; Karl Steinberg, MD, CMD; Gregory Gahm, MD; Peter Winn, MD, CMD; Nancy Losben, R.Ph., CCP, FASCP, CG&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Technical Writer&lt;/em&gt;: Eleanor Mayfield&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;AMDA Staff&lt;/em&gt;: Jacqueline Vance, RN, C. CDONA/LTC, CPG Project Manager, Director of Clinical Affairs&lt;/p&gt;&#xD;&#xA;&lt;p&gt;*Steering Committee Member&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;All contributors must submit an Accreditation Council for Continuing Medical Education (ACCME) approved disclosure form prior to being accepted as a volunteer member of the guideline workgroup. This disclosure form is reviewed by the chair of the American Medical Directors Association (AMDA) Clinical Practice Committee. If any conflicts are perceived, that person is not accepted to be part of the workgroup.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: American Medical Directors Association (AMDA). COPD management in the long-term care setting. Columbia (MD): American Medical Directors Association (AMDA); 2003. 32 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: None available&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the American Medical Directors Association, 10480 Little Patuxent Pkwy, Suite 760, Columbia, MD 21044. Telephone: (800) 876-2632 or (410) 740-9743; Fax (410) 740-4572. Web site: &lt;a href=&quot;http://www.amda.com/&quot; title=&quot;AMDA Web site&quot;&gt;www.amda.com&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Sample performance measurement indicators are provided in Table 18 of the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI on July 6, 2004. The information was verified by the guideline developer on August 4, 2004. This summary was updated by ECRI on December 5, 2005 following the U.S. Food and Drug Administration (FDA) advisory on long-acting beta2-adrenergic agonists (LABA). This NGC summary was updated on October 4, 2011. The updated information was verified by the guideline developer on November 29, 2011. This summary was updated by ECRI Institute on January 14, 2013 following the revised U.S. Food and Drug Administration advisory on Chantix (varenicline). This summary was updated by ECRI Institute on October 25, 2013 following the U.S. Food and Drug Administration advisory on Fluoroquinolone Antibacterial Drugs. This summary was updated by ECRI Institute on April 8, 2015 following the U.S. Food and Drug Administration advisory on Chantix (varenicline).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is copyrighted by the American Medical Directors Association (AMDA) and the American Health Care Association. Written permission from AMDA must be obtained to duplicate or disseminate information from the original guideline. For more information, contact AMDA at (410) 740-9743.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
